| |
|
Last Poster |
Posts |
Pages |
Last Post |
| |
|
|
|
|
|
|
| Author |
Message |
     hershy
Member
Username: hershy
Post Number: 1925
Registered: 10-2002
Rating: N/A
Votes: 0
|
| | Sunday, February 11, 2007 - 11:34 am: |  
|
From the Yahoo finance site:
Acambis: serving vaccinationsBased in the two Cambridges, one in England and the other in Massachusetts, Acambis is a biopharmaceutical company that focuses its resources on the realm of vaccinations, from research to production.It is particularly involved in vaccinations that have largely been forgotten, such as smallpox. Although it was abandoned since the official elimination of the disease in 1977, the possibility of bio-terrorist attacks has meant that the American government has become the first customer of Acambis for smallpox vaccinations. While this is undoubtedly a godsend, it should not overshadow the endless research carried out by the group into other types of infection such as typhoid, Japanese encephalitis and bacteria that resist antibiotics.Acambis has affirmed its global position since December 1999 when it forged a strategic partnership with Baxter and linked up with the Pasteur institute for research purposes.
~~~~~~~~~~~~~
Acambis PLC announces Update on US MVA procurement
Tuesday November 14, 2:03 am ET
Cambridge, UK--(MARKET WIRE)--Nov 14, 2006 -- Update on US Government MVA procurement
Cambridge, UK and Cambridge, Massachusetts - 14 November 2006 - Acambis plc ("Acambis") (LSE: ACM; NASDAQ: ACAM) announces that it has received notification from the US Department of Health and Human Services ("HHS") that its proposal is no longer being considered for award as part of the US Government's Modified Vaccinia Ankara ("MVA") smallpox vaccine tender process.
ADVERTISEMENT
Acambis received notification late yesterday that HHS has re-evaluated Acambis' technical proposal and found that its proposal is no longer in the competitive range for award. As such, Acambis is no longer eligible to receive a contract. Acambis plans to request a meeting to gain further clarification, following which it will consider its options. The US National Institutes of Health has indicated that it intends to continue Acambis' existing MVA contracts at their current price and scope.
Gordon Cameron, Chief Executive Officer, said:
"We are surprised that the US Government would eliminate Acambis from the RFP process. We believe that our proposal would have met the requirements of the US Government, especially given Acambis' track record in the biodefence field."
As one would expect, this was not news well taken by the LSE resulting in a 41% drop in share price.
now ACM is delisting from the NYSE and will be listed only in the UK.
I was lucky enoug to be short ACM but only for 10 shares and made a profit of 10 pounds - but that's another story.
Since then ACM has been clawing it's way upwards and may be trying to close this huge gap.
Retest first ?
"The safest way to double your money is to fold it over and put it back in your pocket."
http://members.optusnet.com.au/~hershy/
|
|
Threads by Last Post Time: First
Previous
102
103
104
105
106
107
108
109
110
111
Next
Last
|
